Stockscreener 앱 받기
9.05
0.60%
-0.07
전일 마감가:
$9.12
열려 있는:
$9.04
하루 거래량:
233.98K
Relative Volume:
0.21
시가총액:
$873.55M
수익:
$247.00M
순이익/손실:
$-249.00M
주가수익비율:
-2.9288
EPS:
-3.09
순현금흐름:
$-267.00M
1주 성능:
+9.89%
1개월 성능:
+31.96%
6개월 성능:
-40.71%
1년 성능:
-42.26%
1일 변동 폭
$8.775
$9.10
1주일 범위
$7.85
$9.35
52주 변동 폭
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
RCUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
9.05 | 873.55M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.48 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.18 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.33 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.92 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.72 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result - GuruFocus
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Long Term Trading Analysis for (RCUS) - news.stocktradersdaily.com
Wells Fargo & Company MN Has $575,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Taking the lead: Arcus Biosciences Inc (RCUS) - Sete News
Arcus Biosciences Inc (RCUS) Stock: Navigating a Year of Volatility - investchronicle.com
Can you now get a good deal on Arcus Biosciences Inc’s shares? - uspostnews.com
Arcus Biosciences Inc [RCUS] Investment Guide: What You Need to Know - knoxdaily.com
Arcus Biosciences Inc (NYSE: RCUS) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Invesco Ltd. - Defense World
Barclays Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $14.00 - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
RCUSArcus Bioscience Latest Stock News & Market Updates - Stock Titan
Are Arcus Biosciences Inc (RCUS) shares a good deal now? - uspostnews.com
Russell Investments Group Ltd. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences to Present First Combination Data for HIF-2a I - GuruFocus
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting | RCUS Stock News - GuruFocus
Groundbreaking Kidney Cancer Treatment Data: Arcus Reveals First Casdatifan-Cabozantinib Results at ASCO 2025 - Stock Titan
Arcus Biosciences Inc (RCUS) Is A Buy According To Analysts - Marketing Sentinel
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences - Benzinga
Arcus Biosciences (RCUS) Price Target Slashed by Barclays to $14 - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update | RCUS Stock News - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update - Business Wire
Geode Capital Management LLC Decreases Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
ARCUS BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain restricted stock units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain Options of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Alliancebernstein L.P. - Defense World
Norges Bank Buys Shares of 34,044 Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Vanguard Group Inc. Sells 79,539 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Corebridge Financial Inc. Sells 2,258 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
American Century Companies Inc. Increases Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants - Bluefield Daily Telegraph
Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies - Investing.com Australia
Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies By Investing.com - Investing.com South Africa
Arcus Biosciences' SWOT analysis: biotech stock's potential in cancer therapies - Investing.com
RCUS stock touches 52-week low at $7.5 amid market challenges - Investing.com Australia
RCUS stock touches 52-week low at $7.5 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
(RCUS) Trading Signals - news.stocktradersdaily.com
Institutional owners may consider drastic measures as Arcus Biosciences, Inc.'s (NYSE:RCUS) recent US$134m drop adds to long-term losses - simplywall.st
Arcus Biosciences patents new c-Kit inhibitors - BioWorld MedTech
Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo
RCUS stock touches 52-week low at $8.81 amid market challenges - Investing.com
Cancer Therapy Pioneer Arcus Biosciences Accelerates Growth with Key Team Expansion - Stock Titan
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Amundi - Defense World
RCUS stock touches 52-week low at $8.97 amid market challenges - Investing.com Australia
RCUS stock touches 52-week low at $8.97 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):